Monday, November 4, 2024
HomeTagsATH434

ATH434

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that the Italian Medicines Agency, or Agenzia Italiana del...

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model

Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that data in an animal model of Multiple...

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that the New Zealand Medicines...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics